GemPharmatech Co., Ltd. (SHA:688046)

Market Cap	14.05B +91.9%
Revenue (ttm)	878.13M +21.7%
Net Income	182.55M +74.9%
EPS	0.45 +79.3%
Shares Out	408.97M
PE Ratio	76.06
Forward PE	70.10
Dividend	0.22 (0.55%)
Ex-Dividend Date	Jun 9, 2026

Volume	23,446,175
Open	35.13
Previous Close	36.70
Day's Range	33.36 - 35.80
52-Week Range	12.89 - 43.47
Beta	0.86
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About GemPharmatech

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, knock-in mouse, point-mutation mouse, transgenic mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,590
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688046

Financial Performance

In 2025, GemPharmatech's revenue was 793.39 million, an increase of 15.51% compared to the previous year's 686.84 million. Earnings were 142.64 million, an increase of 29.88%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 22, 2026

Data Sources Report a data error